Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination EyedropsReport as inadecuate




Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops - Download this document for free, or read online. Document in PDF available to download.

BioMed Research International - Volume 2015 2015, Article ID 435874, 6 pages -

Research ArticleDepartment of Ophthalmology, Soonchunhyang University College of Medicine, Soonchunhyang University Seoul Hospital, Seoul 140-743, Republic of Korea

Received 27 March 2015; Revised 29 May 2015; Accepted 31 May 2015

Academic Editor: Toru Nakazawa

Copyright © 2015 Du Ri Seo and Seung Joo Ha. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To compare the ocular pulse amplitude OPA lowering effects of preservative-free tafluprost and dorzolamide-timolol fixed combination DTFC using dynamic contour tonometry. Methods. In total, 66 eyes of 66 patients with normal tension glaucoma NTG or primary open angle glaucoma POAG were included. Patients were divided into two groups: the preservative-free tafluprost-treated group and the preservative-free DTFC-treated group . Intraocular pressure IOP was measured using Goldmann applanation tonometry GAT. OPA was measured using dynamic contour tonometry; corrected OPA cOPA was calculated at baseline and at 1 week and 1, 3, and 6 months after treatment. Results. After 6 months of treatment, tafluprost significantly reduced IOP . The OPA lowering effects differed significantly between the two treatment groups . The cOPA-lowering effect of tafluprost 1.09 mmHg was significantly greater than that of DTFC 0.36 mmHg after 6 months of treatment . Conclusions. Tafluprost and DTFC glaucoma treatments provided marked OPA and IOP lowering effects. Tafluprost had a greater effect than DTFC; thus, this drug is recommended for patients at risk of glaucoma progression, due to the high OPA caused by large fluctuations in IOP.





Author: Du Ri Seo and Seung Joo Ha

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents